212 search results for: Pathophysiology
World Congress of Dermatology (WCD) 2023 | Singapore
Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.
Bullous Pemphigoid: Insights and Innovation
Watch Dr. Donna Culton, Prof. Dédée Murrell, and Prof. Ulrike Raap at EADV 2025 as they explore the clinical presentation and diagnosis of BP and break down the underlying pathophysiology including the roles of autoimmunity and key inflammatory pathways such as Type 2 inflammation. The experts also discuss the evolving therapeutic landscape and how new insights are shaping future treatment strategies.
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
ADVENT Dermatology Symposium in Denver, CO, USA
This 2-hour educational program delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, bullous pemphigoid, and chronic spontaneous urticaria. It will highlight both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies. Experts will guide the audience through diverse patient cases to illuminate diagnostic nuances and the pathophysiology of each condition. These cases will also highlight the importance of shared decision-making and the broadening of treatment goals beyond symptom control. Dynamic panel discussion and active audience participation will be facilitated through real-time polling and curated Q&A sessions.
ADVENT On Air | Role of Type 2 Inflammation in COPD
Drs Stephanie Christenson and Jean Bourbeau explore the role of type 2 inflammation in Chronic Obstructive Pulmonary Disease (COPD).
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis
Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.
UEGW 2024 | Something to Chew On: Exploring Biologics in EoE Management
Prof. Salvatore Oliva and Dr. Milli Gupta discuss the importance of long-term care, multidimensional assessment, and the latest data for biologics.
UEGW 2024 | Something to Chew On: Exploring Biologics in EoE Management
Prof. Salvatore Oliva and Dr. Milli Gupta discuss the importance of long-term care, multidimensional assessment, and the latest data for biologics.
European Academy of Allergy and Clinical Immunology (EAACI) 2023 | Hamburg
Presentation highlights from the ADVENT symposium at the EAACI 2023 congress in Hamburg, Germany.
The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers
Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.
Mechanisms of Production and Clinical Impact of IgE
Explore how type 2 inflammation drives the production of IgE in severe asthma
